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Dear friends,
Because you have supported diabetes research at the University of Minnesota, we are pleased
to send you this inaugural issue of Discoveries in Diabetes, a publication that highlights our
leading-edge work in this area.
You will get this newsletter twice a year and—if we have your e-mail address—e-updates
in between. To make sure you’re among the first to hear about diabetes breakthroughs at the
University, please send an e-mail to Angela Lillie at a.lillie@mmf.umn.edu with “E-newsletter”
in the subject line. If you’d like to receive a paper copy of these updates, call Angie at
612-625-9646 and she’ll add your name to our list.
We look forward to sharing our exciting diabetes news with you. If you have ideas for upcoming
newsletters or want to share your thoughts on the current issue, feel free to contact me directly
at 612-625-0497 or j.gorell@mmf.umn.edu.
Thank you so much for your generous support of our mission.
Sincerely,
Jean C. Gorell, CFRE
Director of Development, Diabetes
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Key to diabetes care is managing how the
body handles sugar. Glucose is stored as glycogen
in tissues throughout the body until it’s called on
to provide energy. But little is known about what
happens to glycogen stored in the brain.
“What glycogen is doing there and whether it’s
metabolically active hasn’t been defined, particularly
in humans,” explains Elizabeth Seaquist, M.D., a
professor of endocrinology and diabetes at the
University of Minnesota. “We haven’t had a way
to measure it.”
Seaquist, who holds the Pennock Family
Land-Grant Chair in Diabetes Research, has long
suspected that glycogen content in brain tissue may
change dramatically in people with type 1 diabetes
who suffer from hypoglycemia unawareness. These
patients, who’ve lost the ability to sense when their
blood sugar is low, might develop large concentra-
tions of brain glycogen, a compensatory response
to prolonged periods of low blood sugar. Moreover,
that glycogen might be metabolized in a unique way.
Two years ago, Seaquist and an interdisciplinary
team of investigators at the University’s Center for
Magnetic Resonance Research—one of the world’s
top imaging labs—began to test whether it’s
possible to see changes in brain glycogen using
high-field magnetic spectroscopy.
They gave healthy subjects a non-radioactive
isotope that gets incorporated into glycogen in the
brain and then slowly lowered subjects’ blood
sugar. As the research participants lay in the hull
of the magnet, investigators monitored the tagged
molecules to see whether brain glycogen changed
over time.
The results were clear. Researchers were able to
quantify brain glycogen and see marked decreases
after hypoglycemia. They were even able to
determine how long it took for healthy brains
to put the glycogen to use.
“Using spectroscopy, we’re able to measure
brain glycogen content as we’ve never been able
to before,” Seaquist says.
Now her team is beginning to study patients
with type 1 diabetes who have hypoglycemia
unawareness, comparing their brain glycogen
metabolism with the measurements from healthy
subjects. The results may reveal more about the
conditions necessary for the complication to occur.
“As we know more about how hypoglycemia
unawareness happens,” Seaquist says, “we’ll have
a leg up on developing therapies to prevent it.”
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Nearly a decade ago, Bernhard Hering, M.D., and his team were making strides for patients
suffering from a dangerous complication of type 1 diabetes known as hypoglycemia unawareness.
Hering’s group was among the first in the world to bring islet-cell transplantation to clinical
trials, hoping to restore sensitivity to low blood sugar levels for the 12 percent of people with type 1
diabetes who no longer feel important warning signs like shakiness when their blood sugar
plummets, which can result in a loss of consciousness or even brain damage.
The results of the first four islet-cell clinical trials at the
University of Minnesota’s Diabetes Institute for Immunology and
Transplantation far surpassed expectations.
In nearly 90 percent of patients who received a transplant—
consisting of a mere teaspoon-sized infusion of insulin-producing
islet cells from a donor pancreas—the procedure not only cured
hypoglycemia unawareness, but it also eliminated the need for
daily shots of insulin, at least temporarily. Fifty percent of people
in the trial were still insulin-independent after five years.
“The proof of concept has been shown,” says Hering, who
holds the Eunice L. Dwan Diabetes Research Chair and serves
as scientific director of the Diabetes Institute. “We can reverse
diabetes with a cell-based therapy.”
Now Hering’s group has initiated a critical round of studies to
refine the course of treatment and improve long-term outcomes.
The goal is to improve the immunosuppression that’s required
to keep recipients from rejecting the donated cells. The agents
they’re investigating include antibodies given at the time of the
transplant that may enhance islet-cell longevity as well as new
drugs that may replace the potent immunosuppressive medication
typically used in transplant surgery, which can be damaging to
the kidneys. continued on page 2
University team continues to lead the charge
toward a diabetes cure using islet transplants
Surgeon Bernhard Hering, M.D., is
leading part of a national clinical
trial aimed at improving long-term
outcomes of islet-cell transplants.
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But there’s no doubt that successful islet
transplants can be life-changing for patients.
Forty-four-year-old Stephanie Arneson grew
up vigilant about monitoring her blood sugar.
“You never get a day off from diabetes,” she says.
Then, in 1999, she stopped sensing the
signals of hypoglycemia and started passing out
unexpectedly. For the energetic mother of two
young girls, frequent finger pricks and strategic
eating weren’t maintenance enough. When she
blacked out while driving, knocking into a
cement wall on an exit ramp, she knew
something had to change.
Arneson signed on for one of the early clinical
trials at the Diabetes Institute. Despite initial
setbacks, which are now rare, the islet-cell
transplant that took prompted an instant
turnaround. Arneson was able to feel signs of
low blood sugar again.
Now she’s gone five years without needing
a single insulin shot, taking only daily immuno-
suppressive medication to keep her body from
rejecting the transplanted tissue.
The hardest part today, she says, “is explain-
ing to people, ‘Well, I used to have diabetes.’”
Hering’s group hopes that more people will
have to offer that explanation in the near future.
The Diabetes Institute is one of three principal
sites in the United States conducting phase III
trials, the final round of study before applying for
licensure from the Food and Drug Administration,
to determine whether human islets can be used
as a standard therapy for diabetes.
“This will be a landmark achievement,”
says Hering. “It will really open the door to more
opportunities for patients.”
For people who have diabetes, the use of
islet-cell transplantation to eliminate the need
for insulin injections holds great promise.
But the supply of islet cells available for
those transplants is limited. The cells typically
come from the pancreases of deceased donors,
and it sometimes takes cells from two or three
donor pancreases to reverse diabetes in one
person.
In 2006, research
led by University of
Minnesota innovator
Bernhard Hering,
M.D., showed that
islet cells from pigs could be used to reverse
diabetes in monkeys. He thinks that pig islet
cells could be used to reverse diabetes in
humans as well.
But first Hering would need a safe source of
high-quality pigs from which to harvest the cells.
Enter Spring Point Project, a nonprofit
organization founded by entrepreneur Thomas
Cartier that aims to expedite the widespread
availability of islet cells for transplantation by
creating a source of disease-free pig islet cells
at a secure, sterile facility.
Cartier’s son Cory was diagnosed with type 1
diabetes at age 10. Doctors told the family that there
was no cure—Cory would just have to deal with it.
“When I realized that dealing with it means
watching him take shots and prick his fingers, like
millions of people do, my wife and I said it’s just
not acceptable,” Cartier says.
Today the Spring Point Project facility houses
pigs whose islet cells will someday be used to try
to cure diabetes in humans. Clinical trials at the
University to test this idea are scheduled to begin
in late 2009 or early 2010.
“We’re going to find the answer to this,” Cartier
says. “We’re not going to accept it the way it is.”
Creating
a new
supply
of islet
cells
Leading the charge continued from cover
Hundreds of bikers hit the streets of St. Paul
July 25 and 26 for the ninth annual Lightning
Run rally to support diabetes research at the
University of Minnesota.
More than 1,500 people attended this year’s
weekend of events—which included a kick-off
party with live music, auctions, and an awe-
inspiring motorcycle parade—to benefit the
University’s Diabetes Institute for Immunology
and Transplantation.
This year’s events raised more than
$135,000, including a record-breaking amount
from Saturday evening’s live auction.
Since its inception in 2000, the Lightning
Run has raised more than $1.5 million for the
Diabetes Institute.
Revving up for diabetes at the Lightning Run bike rally
Save the date for
next year’s event:
July 17-18, 2009
Jeff Dobbs had been enthralled by golf since
his childhood days, when he would hit balls
with his dad in the backyard of their New Hope,
Minnesota, home. An avid sportsman, the robust
and enterprising father of four also loved
helicopter skiing, fishing, coaching his children’s
soccer teams, and driving race cars.
When he was diagnosed at age 35 with
type 1 diabetes, he battled its effects but still
tried to keep the disease from interfering with the
activities he loved. “He would tell people he was
with on the trip [about his diabetes], in case he
needed help,” says his wife, Kay, “but it was
something he didn’t share with everyone.”
And Jeff Dobbs was captivated by the idea
of advancing diabetes research. “He was really
passionate about trying to find a cure,” says his
19-year-old daughter, Jennifer, “not for himself,
but for us, his kids, and for people in the future.”
In the mid-1990s, as friends batted around the
idea of creating an annual diabetes fund-raising
golf tournament, Dobbs stepped in with character-
istic vigor. Through ProStaff, the Minneapolis-
based temporary staffing company he had started
from scratch, he helped underwrite the expenses
of the University of Minnesota’s first Golf Classic
“fore” Diabetes Research in 1996. His quiet gesture
ensured that all money raised could go directly
to studies focused on eliminating the disease.
The annual tournament he started has become
a mainstay and a critical source of funding for the
University’s Diabetes Institute for Immunology and
Transplantation. In its 13 years, the tournament has
raised more than $4 million for studies at the
Diabetes Institute.
At this year’s event, which took place on
June 16, the early-bird round of the Golf Classic
“fore” Diabetes Research had a
special meaning for the golfers.
Dubbed “Jeff’s Derby,” the
round was reserved for more
than 120 family members
and friends of Jeff Dobbs,
who died in October 2007
at age 51.
The institute that
Dobbs supported with such
enthusiasm recently honored
his commitment to raising
money for diabetes research by
renaming the endowed chair held by
pioneering physician-scientist David E. R.
Sutherland, M.D., Ph.D., head of the Transplant
Division in the University’s Department of
Surgery and director of the Diabetes Institute.
Historically called the Golf Classic “fore”
Diabetes Research Chair, it’s now called the
Jeffrey Dobbs and David E. R. Sutherland, M.D.,
Ph.D., Diabetes Research Chair.
Kay Dobbs is certain that her husband
would have been astounded by the personal
recognition. “He was just very excited by the
possibilities he saw happening at the institute
and was impressed with the dedication of the
doctors,” she says. “He was motivated to do
everything he could to bring about a cure.”
Giving research a sporting chance
To make a gift to
the Dobbs-Sutherland
Diabetes Research
Chair, visit
www.mmf.umn.edu/
goto/dschair or
contact Jean Gorell
at 612-625-0497 or
j.gorell@mmf.umn.edu.
For more information
about the studies
and requirements for
participating, visit
www.diabetesinstitute.
org or call
612-626-3016.
Lauren, Julia,
Stephanie, and
Rob Arneson
Jeff Dobbs and family
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